Affiliation:
1. Department of Urology, Queen’s University, Kingston, ON K7L 3N6, Canada
Abstract
Uncomplicated recurrent urinary tract infections (rUTIs) in women are associated with episodic bothersome symptoms and have a significant impact on the mental and physical quality of life. Treatment with antibiotics (short- and long-term dosing) results in acute and chronic side effects and costs and promotes general antibiotic resistance. Improved nonantibiotic management of rUTI in women represents a true, unmet medical need. MV140 is a novel sublingual mucosal-based bacterial vaccine developed for the prevention of rUTI in women. Based on observational, prospective, and randomized placebo-controlled studies, MV140 has been shown to safely prevent (or reduce the risk of) UTIs, reduce antibiotic use, overall management costs, and patient burden while improving the overall quality of life in women suffering from rUTIs.
Subject
Infectious Diseases,Microbiology (medical),General Immunology and Microbiology,Molecular Biology,Immunology and Allergy
Reference48 articles.
1. Urinary Tract Infection;Nicolle;Crit. Care Clin.,2013
2. Urinary Tract Infection Syndromes: Occurrence, recurrence, bacteriology, risk factors, and disease burden;Foxman;Infect. Dis. Clin. N. Am.,2014
3. Incidence, severity, help seeking, and management of uncomplicated urinary tract infection: A population-based survey;Butler;Br. J. Gen. Pr.,2015
4. Diagnosis and management of simple and complicated urinary tract infections (UTIs);Mazzulli;Can. J. Urol.,2012
5. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline;Anger;J. Urol.,2019
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献